Engineered HEK293 Cell Line for EB-VLP Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing Epstein-Barr virus-like particles (EB-VLPs) for vaccine development are inefficient and result in a mixture with high levels of extracellular vesicles, which complicates purification and increases the risk of host cell proteins in the final product, necessitating a method to enhance the yield and purity of EB-VLPs.
Innovation Solution
A HEK293 cell line is engineered by introducing a vector with the EBV genome capable of autonomous replication, with nucleotide sequences required for prokaryotic propagation removed, and inducing the lytic cycle using a hormone-regulated BZLF1 allele, resulting in a higher ratio of EB-VLPs to extracellular vesicles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If standard methods are used to produce EB-VLPs, then the production process is simple, but the yield and purity of EB-VLPs are low with high levels of extracellular vesicles
Solution Approach 1:
The EBV genome is segmented into two parts: a minimal replicon containing essential replication origins and a separate expression cassette containing viral genes. This segmentation allows the minimal replicon to maintain genomic stability in host cells while the expression cassette provides controlled viral protein production, thereby increasing EB-VLP yield and purity without excessive complexity
Solution Approach 2:
The invention extracts and removes non-essential viral genes from the full EBV genome, retaining only the minimal replicon elements necessary for autonomous replication. This extraction eliminates the production of extracellular vesicles and harmful viral proteins while maintaining EB-VLP production capability, significantly improving product purity
Solution Approach 3:
The vector is designed with different functional regions having specialized properties: the minimal replicon region provides stable maintenance and replication, while the expression cassette region provides controlled viral protein expression. This local differentiation of functional regions optimizes EB-VLP production while minimizing unwanted viral activities
2Productivity
If the full EBV genome is used in the vector, then the virus can replicate autonomously, but the production mixture contains high levels of extracellular vesicles and host cell proteins
Solution Approach 1:
The invention extracts and removes genes encoding extracellular vesicle components and non-essential viral proteins from the full EBV genome. The minimal replicon retains only the origin of replication and essential replication functions, eliminating the generation of harmful extracellular vesicles and host cell protein contamination while maintaining EB-VLP production
Solution Approach 2:
The invention converts the potential harm of viral genome instability into a benefit by designing a minimal replicon that intentionally lacks genes for harmful viral proteins. This controlled minimization prevents the production of extracellular vesicles and toxic viral proteins while maintaining essential replication functions for EB-VLP yield
Data Source
AI summary
The invention provides a method for manufacturing a HEK293 cell line, which is capable of producing Epstein-Barr virus-like particles (EB-VLPs), as well as the HEK293 cell line obtainable by said method. The invention is further directed to a method for manufacturing EB-VLPs and a composition comprising EB-VLPs obtainable by said method for manufacturing EB-VLPs. Additionally, the invention provides a kit comprising EB-VLPs generated according to the method for manufacturing EB-VLPs. Further, the invention relates to a method for manufacturing a vaccine as well as the vaccine containing EB-VLPs obtainable by said method for manufacturing EB-VLPs.